NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.25 AUD | +3.22% |
|
-0.16% | -22.91% |
| Apr. 24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
| Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 248.4 | 147.3 | 474.9 | 1,001 | 3,178 | 2,382 | - | - |
| Enterprise Value (EV) 1 | 234.6 | 123.1 | 438.1 | 961.2 | 3,178 | 2,146 | 2,037 | 1,917 |
| P/E ratio | -23 x | -14.9 x | -57.1 x | 7,950 x | 20.8 x | 25.7 x | 25 x | 12.7 x |
| Yield | - | - | - | - | - | - | - | 4.1% |
| Capitalization / Revenue | 245 x | 153 x | 131 x | 58.8 x | 13.7 x | 15.5 x | 13.7 x | 7.47 x |
| EV / Revenue | 231 x | 128 x | 120 x | 56.4 x | 13.7 x | 14 x | 11.7 x | 6.01 x |
| EV / EBITDA | -21.2 x | -14.4 x | -56.3 x | -606 x | 15.9 x | 18 x | 16.6 x | 7.31 x |
| EV / FCF | -20 x | -15.2 x | -43.9 x | 269 x | - | 28.3 x | 16.1 x | 10.7 x |
| FCF Yield | -5% | -6.57% | -2.28% | 0.37% | - | 3.53% | 6.23% | 9.39% |
| Price to Book | - | - | 12.4 x | 24.1 x | - | 7.42 x | 5.82 x | 4.82 x |
| Nbr of stocks (in thousands) | 100,168 | 114,608 | 125,966 | 125,966 | 127,266 | 127,696 | - | - |
| Reference price 2 | 2.480 | 1.285 | 3.770 | 7.950 | 24.97 | 18.65 | 18.65 | 18.65 |
| Announcement Date | 2/25/20 | 2/23/21 | 2/23/22 | 2/23/23 | 2/29/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.016 | 0.964 | 3.636 | 17.03 | 231.9 | 153.7 | 173.6 | 318.8 |
| EBITDA 1 | -11.07 | -8.556 | -7.786 | -1.586 | 199.2 | 119.1 | 123.1 | 262.1 |
| EBIT 1 | -10.56 | -8.562 | -7.794 | -1.596 | 199.2 | 124.2 | 113.3 | 216.2 |
| Operating Margin | -1,038.88% | -888.17% | -214.36% | -9.37% | 85.9% | 80.75% | 65.24% | 67.8% |
| Earnings before Tax (EBT) 1 | -10.82 | -9.193 | -7.794 | 0.184 | 205.1 | 146.4 | 145.4 | 270.3 |
| Net income 1 | -10.82 | -9.193 | -7.794 | 0.184 | 157.1 | 92.5 | 96.41 | 188.5 |
| Net margin | -1,064.57% | -953.63% | -214.36% | 1.08% | 67.73% | 60.17% | 55.54% | 59.13% |
| EPS 2 | -0.1080 | -0.0860 | -0.0660 | 0.001000 | 1.201 | 0.7269 | 0.7468 | 1.474 |
| Free Cash Flow 1 | -11.73 | -8.084 | -9.98 | 3.58 | - | 75.73 | 126.8 | 179.9 |
| FCF margin | -1,154.63% | -838.59% | -274.48% | 21.02% | - | 49.26% | 73.06% | 56.42% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 63.56% | 103.07% | 68.64% |
| FCF Conversion (Net income) | - | - | - | 1,945.65% | - | 81.87% | 131.55% | 95.42% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 0.7638 |
| Announcement Date | 2/25/20 | 2/23/21 | 2/23/22 | 2/23/23 | 2/29/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.733 | 0.554 | 0.41 | - | 3.402 | 0.283 | 16.75 | 64.4 | 169 | 28.8 | 162.9 |
| EBITDA 1 | -3.168 | -4.758 | -3.798 | - | - | - | - | 49.63 | 151.1 | 11.5 | 143.1 |
| EBIT | -2.931 | -4.761 | -3.801 | - | - | -5.904 | 4.308 | 49.62 | 151.1 | - | - |
| Operating Margin | -399.86% | -859.39% | -927.07% | - | - | -2,086.22% | 25.72% | 77.05% | 89.4% | - | - |
| Earnings before Tax (EBT) | -2.931 | -4.761 | -4.432 | - | - | - | - | 49.62 | 155.5 | - | - |
| Net income 1 | -2.931 | -4.761 | -4.432 | -7.964 | 0.17 | -7.054 | 7.238 | 47.8 | 109.3 | 8 | 104.1 |
| Net margin | -399.86% | -859.39% | -1,080.98% | - | 5% | -2,492.58% | 43.21% | 74.23% | 64.66% | 27.78% | 63.9% |
| EPS 2 | - | - | - | - | - | - | - | 0.3680 | 0.8330 | 0.5100 | 0.5600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 8/25/20 | 2/23/21 | 8/24/21 | 2/23/22 | 8/23/22 | 2/23/23 | 8/27/23 | 2/29/24 | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 13.8 | 24.2 | 36.8 | 40.2 | - | 236 | 344 | 465 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -11.7 | -8.08 | -9.98 | 3.58 | - | 75.7 | 127 | 180 |
| ROE (net income / shareholders' equity) | -78.1% | -48.3% | -24.6% | 0.46% | - | 30.6% | 24.2% | 34.6% |
| ROA (Net income/ Total Assets) | -75.1% | -46.7% | -24% | - | - | 22% | 27% | - |
| Assets 1 | 14.41 | 19.68 | 32.5 | - | - | 420.5 | 357.1 | - |
| Book Value Per Share 2 | - | - | 0.3000 | 0.3300 | - | 2.510 | 3.210 | 3.870 |
| Cash Flow per Share 2 | -0.1200 | -0.0800 | -0.0800 | - | - | 0.4600 | 0.4500 | 1.060 |
| Capex 1 | - | - | 0.01 | 0.02 | - | 0.36 | 0.2 | - |
| Capex / Sales | - | - | 0.28% | 0.11% | - | 0.23% | 0.11% | - |
| Announcement Date | 2/25/20 | 2/23/21 | 2/23/22 | 2/23/23 | 2/29/24 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
18.65
AUD
Average target price
26.74
AUD
Spread / Average Target
+43.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.91% | 1.55B | |
| +25.83% | 661B | |
| +26.74% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.60% | 231B | |
| +5.30% | 200B | |
| -8.92% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NEU Stock
- Financials Neuren Pharmaceuticals Limited
